Harmful diagnostic errors may be occurring in as many as 1 in every 14 (7%) hospital patients—at least those receiving general medical care—suggest the findings of a single… read more.
A new survey shows that Americans’ attitudes toward experiments on animals have changed significantly in recent years, with the vast majority now favoring phasing out animal experiments in… read more.
AbbVie announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of mirvetuximab soravtansine… read more.
An ultrasound test that detected 96% of ovarian cancers in postmenopausal women should replace current standard of care test in the UK according to a new study. In… read more.
A study of more than 28,000 pregnancies from 2022 has found that the majority of pregnant people received the COVID-19 vaccine during its initial release. The study, co-led… read more.
Amgen announced Tepezza has been approved for the treatment of active or high clinical activity score (CAS) Thyroid Eye Disease (TED) by Japan’s Ministry of Health, Labour and Welfare (MHLW)…. read more.
Currently there are no cures for rheumatoid arthritis (RA) which affects 40,000 people in Ireland. The disease costs an estimated €20,000 per patient, per year with an overall… read more.
The Ontario Institute for Cancer Research (OICR) continues to support Ontario drug discovery research by funding high-quality investigations of new therapies for some of the most prevalent pediatric… read more.
Trifluridine–tipiracil with bevacizumab is NICE recommended, within its marketing authorisation, for treating metastatic colorectal cancer in adults who have had 2 lines of treatment (including fluoropyrimidine-, oxaliplatin- and irinotecan-based… read more.
The study, published in Lancet Neurology, detailed the “head-to-head” trial implemented by the researchers to test two drugs, mexiletine and lamotrigine, on people with the condition. The trial, which… read more.
With a fresh wave of free COVID-19 rapid tests now shipping to households nationwide, and many other types of at-home medical tests now available on store shelves and… read more.
Bristol Myers Squibb announced that the FDA has approved Cobenfy (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults. Cobenfy represents the first… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
